Elevar Therapeutics and Inceptua partner to commercialize Apealea®

By Akshay Kedari  | Date: 2020-12-29

Elevar Therapeutics and Inceptua partner to commercialize Apealea®

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel treatment Apealea® in Europe. 

For the uninitiated, Elevar Therapeutics is a Utah-headquartered organization that focuses on offering medical services to patients who have inadequate or limited therapeutic options. Their patent treatment Apealea® is a water-soluble, intravenously injectable chemotherapy agent that is primarily used to treat ovarian cancer as well as other solid tumors.

Reportedly, the recent collaboration is aimed at leveraging Inceptua’s capabilities in oncology development as well as orphan treatments to strengthen the presence of Apealea® in the European market and optimize the value of its portfolio on a global level.

As per the contract, Inceptua will be granted exclusive rights for the distribution and commercialization of the drug across Europe. However, these rights do not permit the administration in Nordic countries including Iceland, Sweden, Norway, Finland, and Denmark.

Stefan Fraenkel, Chief Executive Officer of Inceptua, was reported saying that the company has observed great potential in Apealea® for treatment of ovarian cancer among patients who have a low tolerance for paclitaxel formulated with cremophor. The organization’s established sales force, vast market access capabilities, and robust distribution networks will bolster the commercialization of the treatment throughout Europe, he added.

It is to be noted that Apealea® was granted marketing authorization by regulatory authorities for its administration in the European Economic Area in November 2018, in combination with carboplatin for treating adult patients diagnosed with platinum-sensitive epithelial ovarian cancer. The treatment has recently been granted Orphan Drug Designation by the U.S. FDA (Food and Drug Administration), as cited by credible sources.

About Inceptua Group

Established in 1997, Inceptua focuses on delivering products and services for clinical trials and providing medication for various patient programs. The company’s primary objectives include offering customer-centric services at all stages of a drug lifecycle, facilitating access to unlicensed medicines, and providing an international commercialization platform for pharmaceutical as well as biopharmaceutical products.  

Source credits –

https://www.prnewswire.com/news-releases/elevar-therapeutics-announces-licensing-agreement-with-inceptua-group-for-commercialization-of-apealea-paclitaxel-micellar-in-europe-301198507.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

By Akshay Kedari

South Korea's largest carmaker Hyundai Motor Group is reportedly planning to invest an additional USD 5 billion in the U.S. by 2025. The company aims to strengthen its collaboration with technological firms in the country. During a visit to Se...

Amazon Smart Commerce to digitize 10 million small businesses in India

Amazon Smart Commerce to digitize 10 million small businesses in India

By Akshay Kedari

E-commerce behemoth Amazon Inc. has reportedly launched a “Smart Commerce” initiative in India, aiming to digitalize 10 million small businesses, allow for USD 10 billion worth in exports, and create 2 million jobs by 2025. During the ...

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

By Akshay Kedari

After Ukraine’s invasion, multinational fast-food giant McDonald's Corp. is reportedly planning to sell all its restaurants in Russia, pulling operations from the nation after 30 years. The world's biggest fast-food chain closed 847 ...

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

By Akshay Kedari

GetHenry, a Berlin-based company that offers couriers and logistics organizations electric last-mile delivery bikes, has reportedly raised USD 17.4 million seed round to grow its operations across Europe. The latest investment round was led by LocalG...

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

By Akshay Kedari

Italian luxury sports car manufacturer Ferrari S.p.A. will equip its much-awaited Purosangue SUV with a 12-cylinder engine, as it focused more on fuel-efficient models. Confirming the news, Ferrari Chief Executive Benedetto Vigna claimed that the com...